Research analysts at Wells Fargo & Company started coverage on shares of Septerna (NASDAQ:SEPN - Get Free Report) in a report released on Tuesday, MarketBeat Ratings reports. The brokerage set an "overweight" rating and a $43.00 price target on the stock. Wells Fargo & Company's price target suggests a potential upside of 78.28% from the stock's current price.
Several other research analysts have also issued reports on SEPN. TD Cowen started coverage on shares of Septerna in a research report on Tuesday. They issued a "buy" rating on the stock. Cantor Fitzgerald assumed coverage on shares of Septerna in a research report on Tuesday. They issued an "overweight" rating and a $50.00 price target on the stock.
Check Out Our Latest Report on Septerna
Septerna Price Performance
NASDAQ:SEPN traded up $0.57 during midday trading on Tuesday, hitting $24.12. 185,032 shares of the stock were exchanged, compared to its average volume of 199,049. Septerna has a one year low of $18.62 and a one year high of $26.34.
Insider Buying and Selling at Septerna
In other Septerna news, major shareholder Rock Ventures V. L.P. Third acquired 370,500 shares of Septerna stock in a transaction that occurred on Monday, October 28th. The stock was acquired at an average price of $18.00 per share, with a total value of $6,669,000.00. Following the purchase, the insider now owns 6,215,591 shares in the company, valued at approximately $111,880,638. This trade represents a 6.34 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
About Septerna
(
Get Free Report)
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
Further Reading
Before you consider Septerna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Septerna wasn't on the list.
While Septerna currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
